Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Michael Hardin who wrote (65397)	3/31/1999 10:37:00 AM
From: songw	Read Replies (2) \| Respond to of 119973

BOSCF 5s + INTC Wednesday March 31, 10:07 am Eastern Time BOS, Better Online Solutions Ltd. Affiliate, SURF Communication Solutions Ltd., Receives Investment from Group Including DS Polaris Ltd. and Intel Corporation TERADYON, Israel--(BUSINESS WIRE)--March 31, 1999--BOS, Better Online Solutions Ltd., (NASDAQ: BOSCF - news; ''BOS'') is pleased to announce that a group of investors, comprised of Intel Corporation, DS Polaris Ltd. and others has made a $4 million investment in BOS' affiliate SURF Communications Solutions, Ltd. (''SURF'' or ''the Company''). ''SURF's strategy is to provide data protocol and management solutions as components to OEMs. Our open system software furnishes SURF's customers with the flexibility to respond effectively to dynamic market demands,'' said Dr. Amnon Gavish, CEO of SURF. ''The investment capital from Intel and Polaris will help us expand our technological base to include solutions for emerging markets such as xDSL.'' BOSCF trading 5s -low end biz.yahoo.com

To: Michael Hardin who wrote (65397)	3/31/1999 10:38:00 AM
From: Caravan	Respond to of 119973

SUGN CBS Marketwatch article from last week Sugen gains: Shares of Sugen Inc, (SUGN), the California developer of cancer treatments, are flirting with a 52-week high. A team at the University of California Los Angeles announced it was starting trials of Sugen's drug, called SU5416, on people with advanced colon cancer. What might really be moving the stock, though, is news in UCLA's press release, which came out Wednesday. In it, the team at UCLA's Jonsson Cancer Center says a previous Sugen study "will be chronicled in a rare two-segment piece on '60 Minutes,' scheduled to air April 4" on CBS. Lee Rosen, principal investigator and head of UCLA's Cancer Therapy Development Program, noted in the release that Sugen's drugs, which are thought to attack tumors by cutting off their blood supply, were being used in tests on human beings before the media started writing about angiogenesis inhibitors and their effects on mice last year. UCLA researchers said they will use SU5416 in combination with the standard chemotherapy treatments for colon cancer. "Researchers already have determined that SU5416 is safe for humans," the press release said.